"Our findings extend previous anecdotal safety signals and provide more systematic evidence to inform clinical awareness of this potential adverse effect," write the researchers
Zepbound (tirzepatide) Approved - A once-weekly injectable medication approved by the FDA in November 2023 for chronic weight management
s , Change in body weight
A practical rotation schedule: abdomen during weeks 1-4, upper thigh during weeks 5-8, upper arm during weeks 9-12, then back to abdomen for maintenance
By 2026 that figure had risen to 11.4% meaning roughly one in nine dollars of employer drug spending now goes to this single medication class
The authors specifically called for future research to measure strength, mobility, and function rather than relying primarily on lean mass